These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
104 related items for PubMed ID: 580991
41. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. Liu JN, Gurewich V. J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471 [Abstract] [Full Text] [Related]
42. The role of placental urokinase inhibitor in toxemia of pregnancy. Terao T, Kobayashi T. Biol Res Pregnancy Perinatol; 1983 Dec; 4(4):145-51. PubMed ID: 6360225 [Abstract] [Full Text] [Related]
43. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S. Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [Abstract] [Full Text] [Related]
44. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase. Moroz LA, Sniderman AD, Marpole DG. N Engl J Med; 1979 Nov 15; 301(20):1100-4. PubMed ID: 158709 [No Abstract] [Full Text] [Related]
45. Antithrombogenicity of UK-immobilized polymer surfaces. Sugitachi A, Tanaka M, Kawahara T, Takagi K. Trans Am Soc Artif Intern Organs; 1980 Nov 15; 26():274-8. PubMed ID: 7018054 [No Abstract] [Full Text] [Related]
46. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC. Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946 [Abstract] [Full Text] [Related]
48. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo]. Badimón L, Villaverde CA, Vidal M, Valdecasas FG. Arch Farmacol Toxicol; 1979 Dec 20; 5(3):262-4. PubMed ID: 397803 [No Abstract] [Full Text] [Related]
50. [Various aspects of the platelets-urokinase interaction]. Bastida E, Villaverde CA, Borruel MT, Valdecasas FG. Arch Farmacol Toxicol; 1979 Dec 20; 5(3):270-1. PubMed ID: 397805 [No Abstract] [Full Text] [Related]
51. Comparative study of different urokinase preparations. Millar WT, Smith JF. Thromb Res; 1983 Jun 01; 30(5):425-9. PubMed ID: 6351343 [Abstract] [Full Text] [Related]
54. [A study of urokinase lysis time in patients with various renal diseases]. Shimizu K, Kishi T, Ootaka M, Yamamoto J, Shibata M, Ban I, Sakai H, Kobayashi K. Nihon Jinzo Gakkai Shi; 1982 Nov 01; 24(11):1233-41. PubMed ID: 6762457 [No Abstract] [Full Text] [Related]
57. Inhibitory effect of decidua on fibrinolysis induced by urokinase and by the fibrinolytic activity of the rat ovum. Liedholm P, Astedt B. Acta Obstet Gynecol Scand; 1976 Nov 01; 55(3):217-9. PubMed ID: 936985 [Abstract] [Full Text] [Related]
58. In vitro and in vivo measurement of total antiplasmin activity. Matsuo O, Mihara H. Thromb Haemost; 1977 Apr 30; 37(2):216-21. PubMed ID: 141753 [Abstract] [Full Text] [Related]